Growth Investor27
reacted to and commented on
$Esperion Therapeutics (ESPR.US)$Undervalued Stock with a Game-Changing Statin Alternative
This is a $0.73 stock with a market cap of approximately $145 million — offering significant upside potential. The company, Esperion Therapeutics, sells two FDA-approved, much-needed statin alternatives: Nexletol and Nexlizet. These medications address a major health need — millions of patients cannot tolerate statins due to side effects but still need to m...
This is a $0.73 stock with a market cap of approximately $145 million — offering significant upside potential. The company, Esperion Therapeutics, sells two FDA-approved, much-needed statin alternatives: Nexletol and Nexlizet. These medications address a major health need — millions of patients cannot tolerate statins due to side effects but still need to m...
33
8
1
Growth Investor27
commented on
🚀 2 Biotech Stocks With Explosive Upside Potential: One Targeting a Mega Squeeze, the Other Tackling a $100B Market
While big pharma grabs headlines, two lesser-known biotech companies — Lexaria Bioscience (LEXX) and Esperion Therapeutics (ESPR) — are quietly positioning themselves for dramatic upside. One is addressing the biggest delivery problem in a $100B+ drug market, the other is potentially on the verge of...
While big pharma grabs headlines, two lesser-known biotech companies — Lexaria Bioscience (LEXX) and Esperion Therapeutics (ESPR) — are quietly positioning themselves for dramatic upside. One is addressing the biggest delivery problem in a $100B+ drug market, the other is potentially on the verge of...
12
7
2
$Esperion Therapeutics (ESPR.US)$ Follow Linkedin posts by Esperion. $Novartis AG (NVS.US)$ is connected. I expect to hear a Big partnership or acquistion. The stock price is extremely undervalued.
1
3
$Esperion Therapeutics (ESPR.US)$Esperion's Promising Future: Strategic Partnerships and Product Innovations Drive Buy Rating
Esperion (ESPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst . Analyst Thomas Shrader from BTIG maintained a Buy rating on the stock and has a $9.00 price target.
Thomas Shrader has given his Buy rating due to a combination ...
Esperion (ESPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst . Analyst Thomas Shrader from BTIG maintained a Buy rating on the stock and has a $9.00 price target.
Thomas Shrader has given his Buy rating due to a combination ...
6
4
Growth Investor27
commented on
$Plug Power (PLUG.US)$ Based on short-term price targets offered by 21 analysts, the average price target for Plug Power comes to $2.00 above.
What is your comments？
What is your comments？
5
2
Growth Investor27
commented on
$Esperion Therapeutics (ESPR.US)$ hi eveyone ? who knows this stock? great news but the proce is still going down ? why ? someone control the stock ? scam ?
1
7
Growth Investor27
liked and commented on
$Esperion Therapeutics (ESPR.US)$Esperion Therapeutics (ESPR): A High-Growth Opportunity with Potential 10x Returns
Esperion Therapeutics (ESPR), currently trading under $2 per share, has been attracting considerable attention from analysts. Recently, three analysts reaffirmed strong "Buy" ratings, with price targets ranging from $5 to $16 per share. Among the nine analysts covering Esperion, seven h...
Esperion Therapeutics (ESPR), currently trading under $2 per share, has been attracting considerable attention from analysts. Recently, three analysts reaffirmed strong "Buy" ratings, with price targets ranging from $5 to $16 per share. Among the nine analysts covering Esperion, seven h...
7
6
2
$Esperion Therapeutics (ESPR.US)$ On Fintel ESPR shows 144 million now owned & being added by JPM MS & GSCO & also BOA. This is a good sign.
4
2
Growth Investor27
liked and commented on
2
2
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iMjYiIGhlaWdodD0iMjYiIHZpZXdCb3g9IjAgMCAyNiAyNiIgZmlsbD0ibm9uZSIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KPHBhdGggZmlsbC1ydWxlPSJldmVub2RkIiBjbGlwLXJ1bGU9ImV2ZW5vZGQiIGQ9Ik0xMi45OTk5IDAuMzI1NDM5QzYuMDQxMTEgMC4zMjU0MzkgMC4zOTk5MDIgNS45NjY2NSAwLjM5OTkwMiAxMi45MjU0QzAuMzk5OTAyIDE5Ljg4NDIgNi4wNDExMSAyNS41MjU0IDEyLjk5OTkgMjUuNTI1NFYyMi43MjU0QzcuNTg3NTEgMjIuNzI1NCAzLjE5OTkgMTguMzM3OCAzLjE5OTkgMTIuOTI1NEMzLjE5OTkgNy41MTMwNSA3LjU4NzUxIDMuMTI1NDQgMTIuOTk5OSAzLjEyNTQ0VjAuMzI1NDM5WiIgZmlsbD0idXJsKCNwYWludDBfbGluZWFyXzIyMDBfNDg2NikiLz4KPHBhdGggZmlsbC1ydWxlPSJldmVub2RkIiBjbGlwLXJ1bGU9ImV2ZW5vZGQiIGQ9Ik0xMyAyNS41MjU0QzE5Ljk1ODggMjUuNTI1NCAyNS42IDE5Ljg4NDIgMjUuNiAxMi45MjU0QzI1LjYgNS45NjY2NSAxOS45NTg4IDAuMzI1NDQgMTMgMC4zMjU0MzlWMy4xMjU0NEMxOC40MTI0IDMuMTI1NDQgMjIuOCA3LjUxMzA1IDIyLjggMTIuOTI1NEMyMi44IDE4LjMzNzggMTguNDEyNCAyMi43MjU0IDEzIDIyLjcyNTRWMjUuNTI1NFoiIGZpbGw9InVybCgjcGFpbnQxX2xpbmVhcl8yMjAwXzQ4NjYpIi8+CjxjaXJjbGUgY3g9IjEzLjAwMDEiIGN5PSIyNC4xMjUzIiByPSIxLjQiIGZpbGw9InVybCgjcGFpbnQyX2xpbmVhcl8yMjAwXzQ4NjYpIi8+CjxkZWZzPgo8bGluZWFyR3JhZGllbnQgaWQ9InBhaW50MF9saW5lYXJfMjIwMF80ODY2IiB4MT0iNy4zOTk5IiB5MT0iMjUuNTI1NCIgeDI9IjcuMzk5OSIgeTI9IjIuNDI1NDQiIGdyYWRpZW50VW5pdHM9InVzZXJTcGFjZU9uVXNlIj4KPHN0b3Agc3RvcC1jb2xvcj0iIzdBN0E3QSIgc3RvcC1vcGFjaXR5PSIwIi8+CjxzdG9wIG9mZnNldD0iMSIgc3RvcC1jb2xvcj0iIzdBN0E3QSIgc3RvcC1vcGFjaXR5PSIwLjUiLz4KPC9saW5lYXJHcmFkaWVudD4KPGxpbmVhckdyYWRpZW50IGlkPSJwYWludDFfbGluZWFyXzIyMDBfNDg2NiIgeDE9IjIwIiB5MT0iMjUuNTI1NCIgeDI9IjIwIiB5Mj0iMi40MjU0NCIgZ3JhZGllbnRVbml0cz0idXNlclNwYWNlT25Vc2UiPgo8c3RvcCBzdG9wLWNvbG9yPSIjN0E3QTdBIi8+CjxzdG9wIG9mZnNldD0iMSIgc3RvcC1jb2xvcj0iIzdBN0E3QSIgc3RvcC1vcGFjaXR5PSIwLjUiLz4KPC9saW5lYXJHcmFkaWVudD4KPGxpbmVhckdyYWRpZW50IGlkPSJwYWludDJfbGluZWFyXzIyMDBfNDg2NiIgeDE9IjEzLjAwMDEiIHkxPSIyNC4xMjUzIiB4Mj0iMTQuNDAwMSIgeTI9IjI0LjEyNTMiIGdyYWRpZW50VW5pdHM9InVzZXJTcGFjZU9uVXNlIj4KPHN0b3Agc3RvcC1jb2xvcj0iIzdBN0E3QSIvPgo8c3RvcCBvZmZzZXQ9IjEiIHN0b3AtY29sb3I9IiM3QTdBN0EiIHN0b3Atb3BhY2l0eT0iMCIvPgo8L2xpbmVhckdyYWRpZW50Pgo8L2RlZnM+Cjwvc3ZnPgo=)
Growth Investor27 : $110 MILLION to $130 MILLION being paid to ESPR this year in milestones from Otsuka, with royalties starting next year at 15% and Canada, Australia & Israel and New Zealend. Then all the royalties diverting back to Esperion from Daiichi Sankyo by 2028 Q3 estimate, bring in $200 million a year by then. Patents extended to 2040. And Triple combo single pill with a statin bring down LDL by 65% is HUGE. The Only STATIN alternative that lowers HSCRP to give additional layer of protection from a HEART ATTACK & STROKE. This stock is crazy undervalued. LOAD & Hold. I take the NEXLIZET myself and have great results with NO side effects.